Ceapro Presents Positive Results from Avenanthramides Study at the 2019 American Society of Sports Medicine Meeting
June 05, 2019 08:00 ET
|
Ceapro Inc.
- Data demonstrated that oat avenanthramides supplementation could inhibit molecules involved in the exercise induced inflammation process EDMONTON, Alberta, June 05, 2019 (GLOBE NEWSWIRE) --...
Ceapro Inc. Commences Patient Enrollment in First-in-Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
June 03, 2019 09:00 ET
|
Ceapro Inc.
– Ceapro at the forefront of pioneering approach with a natural product as add-on therapy to a prescription product – Study evaluating the well-known health claims of beta glucan and its potentially...
Ceapro Inc. Reports 2019 First Quarter Financial Results and Highlights
May 23, 2019 09:00 ET
|
Ceapro Inc.
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development of delivery systems - ...
Ceapro Inc. Announces Receipt of Site License from Health Canada
May 15, 2019 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, May 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. to Present at the ThinkEquity Conference in New York City
April 24, 2019 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, April 24, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. Announces Positive Key Findings from Three Oral Presentations Given at European Meeting on Supercritical Fluids
April 15, 2019 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, April 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. Reports Fourth Quarter and Full Year 2018 Results and Highlights
April 11, 2019 09:00 ET
|
Ceapro Inc.
– 2018 marked by Company’s catalytic pivot from contract manufacturer tobiopharmaceutical company and validation of Ceapro’s dedication to innovation – EDMONTON, Alberta, April 11, 2019 (GLOBE...
Ceapro Announces Acceptance of Abstract for Presentation at the 2019 American College of Sports Medicine Annual Meeting
March 27, 2019 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, March 27, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. Announces Issuance of Indian Patent Application for Enabling Pressurized Gas eXpanded (PGX) Technology
March 25, 2019 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)
February 26, 2019 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...